These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists. Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and SAR of 5-amino- and 5-(aminomethyl)benzofuran histamine H3 receptor antagonists with improved potency. Sun M; Zhao C; Gfesser GA; Thiffault C; Miller TR; Marsh K; Wetter J; Curtis M; Faghih R; Esbenshade TA; Hancock AA; Cowart M J Med Chem; 2005 Oct; 48(20):6482-90. PubMed ID: 16190774 [TBL] [Abstract][Full Text] [Related]
12. A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. Apodaca R; Dvorak CA; Xiao W; Barbier AJ; Boggs JD; Wilson SJ; Lovenberg TW; Carruthers NI J Med Chem; 2003 Aug; 46(18):3938-44. PubMed ID: 12930154 [TBL] [Abstract][Full Text] [Related]
13. Three-dimensional models of histamine H3 receptor antagonist complexes and their pharmacophore. Axe FU; Bembenek SD; Szalma S J Mol Graph Model; 2006 May; 24(6):456-64. PubMed ID: 16386444 [TBL] [Abstract][Full Text] [Related]
14. Structural variations of 1-(4-(phenoxymethyl)benzyl)piperidines as nonimidazole histamine H3 receptor antagonists. Mikó T; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H Bioorg Med Chem; 2004 May; 12(10):2727-36. PubMed ID: 15110854 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of new non-imidazole H3-receptor antagonists of the 2-aminobenzimidazole series. Rivara M; Zuliani V; Cocconcelli G; Morini G; Comini M; Rivara S; Mor M; Bordi F; Barocelli E; Ballabeni V; Bertoni S; Plazzi PV Bioorg Med Chem; 2006 Mar; 14(5):1413-24. PubMed ID: 16263297 [TBL] [Abstract][Full Text] [Related]
16. Piperidine-containing histamine H3 receptor antagonists of the carbamate series: the influence of the additional ether functionality. Łazewska D; Kieć-Kononowicz K; Pertz HH; Elz S; Stark H; Schunack W Pharmazie; 2002 Dec; 57(12):791-5. PubMed ID: 12561236 [TBL] [Abstract][Full Text] [Related]
18. Investigation of the histamine H3 receptor binding site. Design and synthesis of hybrid agonists with a lipophilic side chain. Ishikawa M; Watanabe T; Kudo T; Yokoyama F; Yamauchi M; Kato K; Kakui N; Sato Y J Med Chem; 2010 Sep; 53(17):6445-56. PubMed ID: 20690643 [TBL] [Abstract][Full Text] [Related]
19. Replacement of imidazole by a piperidine moiety differentially affects the potency of histamine H3-receptor antagonists. Liedtke S; Flau K; Kathmann M; Schlicker E; Stark H; Meier G; Schunack W Naunyn Schmiedebergs Arch Pharmacol; 2003 Jan; 367(1):43-50. PubMed ID: 12616340 [TBL] [Abstract][Full Text] [Related]
20. Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists. Berlin M; Lee YJ; Boyce CW; Wang Y; Aslanian R; McCormick KD; Sorota S; Williams SM; West RE; Korfmacher W Bioorg Med Chem Lett; 2010 Apr; 20(7):2359-64. PubMed ID: 20188550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]